137 related articles for article (PubMed ID: 7988033)
1. Lipoprotein profiling by high performance gel chromatography.
Tallis GA; Shephard MD; Whiting MJ
Clin Chim Acta; 1994 Aug; 228(2):171-9. PubMed ID: 7988033
[TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
[TBL] [Abstract][Full Text] [Related]
4. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
[No Abstract] [Full Text] [Related]
5. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
6. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
[TBL] [Abstract][Full Text] [Related]
7. Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
Sirtori CR; Franceschini G; Gianfranceschi G; Vaccarino V; Chiesa G; Maderna P; Bertoli M; Calabresi L
Eur J Epidemiol; 1992 May; 8 Suppl 1():120-4. PubMed ID: 1505648
[TBL] [Abstract][Full Text] [Related]
8. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
Frost PH; Havel RJ
Am J Cardiol; 1998 Feb; 81(4A):26B-31B. PubMed ID: 9526810
[TBL] [Abstract][Full Text] [Related]
9. Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins.
März W; Siekmeier R; Scharnagl H; Seiffert UB; Gross W
Clin Chem; 1993 Nov; 39(11 Pt 1):2276-81. PubMed ID: 8222220
[TBL] [Abstract][Full Text] [Related]
10. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
11. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
[TBL] [Abstract][Full Text] [Related]
14. High correlation but lack of agreement between direct high-performance gel chromatography analysis and conventional indirect methods for determining lipoprotein cholesterol.
Krause BR; Schork NJ; Kieft KA; Smith MP; Maciejko JJ
Clin Chem; 1996 Dec; 42(12):1996-2001. PubMed ID: 8969639
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
Hoeg JM; Maher MB; Zech LA; Bailey KR; Gregg RE; Lackner KJ; Fojo SS; Anchors MA; Bojanovski M; Sprecher DL
Am J Cardiol; 1986 Apr; 57(11):933-9. PubMed ID: 3515897
[TBL] [Abstract][Full Text] [Related]
16. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
[TBL] [Abstract][Full Text] [Related]
17. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints.
Warnick GR; Knopp RH; Fitzpatrick V; Branson L
Clin Chem; 1990 Jan; 36(1):15-9. PubMed ID: 2297909
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein profile in patients who survive a stroke.
Oravec S; Krivosikova Z; Krivosik M; Gruber K; Gruber M; Dukát A; Gavorník P
Neuro Endocrinol Lett; 2011; 32(4):496-501. PubMed ID: 21876499
[TBL] [Abstract][Full Text] [Related]
19. Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias.
Campos CT; Matts JP; Fitch LL; Speech JC; Long JM; Buchwald H
Surgery; 1990 Oct; 108(4):601-10; discussion 610-1. PubMed ID: 2120785
[TBL] [Abstract][Full Text] [Related]
20. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia.
Kwiterovich PO; White S; Forte T; Bachorik PS; Smith H; Sniderman A
Arteriosclerosis; 1987; 7(3):211-25. PubMed ID: 3593067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
